Vascular Biogenics Ltd (NASDAQ:VBLT) has been given an average rating of “Hold” by the six analysts that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $3.33.
Several analysts have commented on the stock. Chardan Capital reiterated a “hold” rating and set a $3.00 target price on shares of Vascular Biogenics in a research report on Tuesday, November 20th. Zacks Investment Research cut shares of Vascular Biogenics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 23rd. Finally, HC Wainwright reiterated a “hold” rating and set a $3.00 target price on shares of Vascular Biogenics in a research report on Monday, August 20th.
VBLT stock opened at $1.21 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.47 and a quick ratio of 11.47. Vascular Biogenics has a fifty-two week low of $1.08 and a fifty-two week high of $8.75. The company has a market capitalization of $42.70 million, a P/E ratio of -3.27 and a beta of -1.29.
Vascular Biogenics (NASDAQ:VBLT) last issued its earnings results on Tuesday, November 20th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). The business had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.30 million. Vascular Biogenics had a negative net margin of 71.83% and a negative return on equity of 18.36%. As a group, sell-side analysts forecast that Vascular Biogenics will post -0.73 EPS for the current fiscal year.
An institutional investor recently bought a new position in Vascular Biogenics stock. First Republic Investment Management Inc. bought a new stake in shares of Vascular Biogenics Ltd (NASDAQ:VBLT) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund bought 270,000 shares of the biopharmaceutical company’s stock, valued at approximately $438,000. First Republic Investment Management Inc. owned about 0.75% of Vascular Biogenics as of its most recent filing with the SEC. Institutional investors own 16.17% of the company’s stock.
Vascular Biogenics Company Profile
Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels.
Featured Article: Cost of Debt
Receive News & Ratings for Vascular Biogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics and related companies with MarketBeat.com's FREE daily email newsletter.